Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The non-Helicobacter pylori gut microbiota refers to the diverse community of microorganisms, including bacteria, archaea, fungi, and viruses, that inhabit the gastrointestinal tract excluding the H. pylori species. This complex ecosystem is essential for maintaining host homeostasis by facilitating the fermentation of non-digestible carbohydrates, synthesizing vitamins such as B12 and K, and providing a barrier against enteric pathogens (Source: Nature Reviews Microbiology, 2016). Beyond digestion, these microbes interact extensively with the host immune system, influencing both local and systemic inflammatory responses (Source: Science, 2017). Dysbiosis, or the imbalance of these microbial populations, has been implicated in the pathogenesis of numerous diseases, including inflammatory bowel disease (IBD), obesity, and Clostridioides difficile infection (Source: Cell, 2019). Therapeutic interventions targeting this microbiota include probiotics, prebiotics, and fecal microbiota transplantation (FMT), which aim to restore a healthy microbial balance (Source: The Lancet, 2017). Recent drug development efforts are also exploring postbiotics and small molecules that specifically modulate microbial metabolic pathways to treat metabolic and autoimmune disorders (Source: Nature Medicine, 2020).
Modulation of microbial community structure, restoration of commensal diversity, competitive inhibition of pathogens, and production of bioactive metabolites like short-chain fatty acids (SCFAs).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-Helicobacter pylori gut microbiota.